Transcode Therapeutics, Inc.
RNAZ· Nasdaq
RNAZTranscode Therapeutics, Inc.
Who holds Transcode Therapeutics, Inc., from the managers’ Form 13F reports for the quarter ended Jun 30, 2026.
Form 13F covers managers with $100 million or more. Positions are as of the quarter end and filed up to 45 days later; the latest quarter fills in as reports land.
| Manager | Shares | Change | Value | Of portfolio | Filed |
|---|---|---|---|---|---|
| Yorkville Advisors Global, LP | 19.6K | New | $122K | 0.1% | Aug 6, 2026 |
| Vanguard Capital Management LLC | 6.5K | ±0% | $40.6K | 0% | Aug 13, 2026 |
| Vanguard Fiduciary Trust Co | 3K | ±0% | $18.5K | 0% | Aug 13, 2026 |
| UBS Group AG | 2.9K | −65.2% | $17.9K | 0% | Aug 13, 2026 |
| FMR LLC | 706 | New | $4.4K | 0% | Aug 13, 2026 |
| Tower Research Capital LLC (TRC) | 677 | +196.9% | $4.2K | 0.1% | Aug 11, 2026 |
| Wells Fargo & Company | 55 | ±0% | $342 | 0% | Aug 14, 2026 |
| SBI Securities Co., Ltd. | 12 | ±0% | $75 | 0% | Jul 23, 2026 |
